← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Histone deacetylase (HDAC) inhibitors
belinostat
L01XH04
Forms & Strengths
- Intravenous powder for reconstitution: 500 mg per vial
Adult Dosing
- 1000 mg/m2 administered as an IV infusion over 30 minutes once daily on days 1 to 5 of a 21-day cycle
- Repeat cycle every 3 weeks until disease progression or unacceptable toxicity
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
Mechanism of Action
- Histone deacetylase (HDAC) inhibitor that inhibits HDAC enzymes (classes I, II, and IV)
- Causes accumulation of acetylated histones and other proteins, inducing cell cycle arrest, apoptosis, and differentiation in cancer cells
Contraindications
- Severe hepatic impairment (Child-Pugh Class B or C)
- Known hypersensitivity to belinostat or its excipients
Adverse Reactions
- Nausea and vomiting
- Fatigue
- Pyrexia
- Anemia
- Thrombocytopenia and neutropenia
- Infections
- Elevated creatinine
Drug Interactions
- Co-administration with strong CYP2A6 inhibitors may increase belinostat exposure
- Co-administration with strong CYP inhibitors/inducers requires caution
- Monitor closely when used with myelosuppressive agents due to additive bone marrow suppression
Curated Content: Needs Vetting Before Put to Clinical Use